Indivior Pharmaceuticals, Inc. Effective Tax Rate
Indivior Pharmaceuticals, Inc. (INDV) reported Effective Tax Rate of 24.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 24.00%, a 66.20% decline year-over-year.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 23.00%, a 21.05% increase year-over-year.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was -14.00%, a 151.85% decline year-over-year.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was 71.00%, a 273.68% increase year-over-year.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 12.20%, a 81.23% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for fiscal 2024 was 65.00%, a 396.18% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for fiscal 2023 was 13.10%, a 73.43% decline from fiscal 2022.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, percent for fiscal 2022 was 49.30%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month | Effective Income Tax Rate Reconciliation, Percent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 24.00% 10-Q · filed 2026-08-03 | 23.00% 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | 23.00% 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | 12.20% 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -14.00% 10-Q · filed 2025-10-30 | 32.00% 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | 71.00% 10-Q · filed 2026-08-03 | 46.00% 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | 19.00% 10-Q · filed 2026-04-30 | ||||
| 2024-12-31 | 65.00% 10-K · filed 2026-02-26 | 76.00% 10-K · filed 2025-03-03 | |||
| 2024-09-30 | 27.00% 10-Q · filed 2025-10-30 | 21.00% 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | 19.00% 10-Q · filed 2025-07-31 | 25.00% 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | 16.00% 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | 13.10% 10-K · filed 2026-02-26 | 13.20% 10-K · filed 2025-03-03 | |||
| 2022-12-31 | 49.30% 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |